Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity

Eitemau Tebyg

• Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy
  gan: Abrams, Stephen L., et al.
  Cyhoeddwyd: (2010)
• p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
  gan: Chappell, William H., et al.
  Cyhoeddwyd: (2012)
• The therapeutic potential of mTOR inhibitors in breast cancer
  gan: Steelman, Linda S., et al.
  Cyhoeddwyd: (2016)
• Recent discoveries in the cycling, growing and aging of the p53 field
  gan: McCubrey, James A., et al.
  Cyhoeddwyd: (2012)
• Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
  gan: Chappell, William H., et al.
  Cyhoeddwyd: (2020)